- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00695344
Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant (EVEROSTAT)
Prospective and Randomized Study to Evaluate the Effect of Everolimus in the Clinical and Intra-Cardiac Ecography Progression of Heart Graft Vascular Illness.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, randomized, multicentre, open and controlled study, to evaluate the efficacy and safety of everolimus combined with cyclosporin for microemulsion and steroids according to medical judgement, opposite to the usual therapy which the patient already has received (typically: ciclosporin + azathioprine or mycophenolate mofetil + steroids according to the judgement of the doctor) for patients receiving a cardiac orthotopic transplant since at least 12 months. The patients will be randomized in a 2:1 proportion (everolimus:control), in order to make it possible for the majority of patients to receive the potentially active treatment in a lethal illness for which there is not efficient known treatment up to date.
The study duration will be 2 years of follow-up for each patient. At the end of this period, the patients will be offered the possibility to maintain the immunosuppressive treatment to which they have been assigned, and periodic revisions will be made each 3-6 months.
The two treatment groups are:
Group I - Everolimus twice a day v.o. + cyclosporin for microemulsion in reduced doses +/- steroids.
Group II - Cyclosporin for microemulsion + azathioprine or mycophenolate mofetil +/- steroids (the same administration schedule and medication which the patient received earlier).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Spain, 08041
- Hospital Santa Creu i Sant Pau
-
Barcelona, Spain, 08907
- Hospital de Bellvitge
-
Madrid, Spain, 28041
- Hospital 12 de Octubre
-
Madrid, Spain, 28007
- Hospital Gregorio Marañón
-
Madrid, Spain, 28035
- Hospital Puerta de Hierro
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Hospital Marqués de Valdecilla
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Clinica Universitaria de Navarra
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients suffering a heart transplantation at least 12 months before the inclusion.
- Patients with significant graft vascular cardiac illness.
Exclusion Criteria:
- Patients who received more than one solid organ.
- Hypersensibility to everolimus.
- Patients with expected surviving less than 6 months.
- Analytic abnormality significant (platelets < 70.000 plat./mm3, WBC<4.000./mm3, creatinine > 2,5 mg/dl)
- Neoplasm and/or severe systemic illness.
- Mental significant illness.
- Patients who have received sirolimus or everolimus in any moment after transplant.
- Pregnant or lactating woman.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: 1
Everolimus 2 times per day + cyclosporin low dose +/- steroids
|
Everolimus 2 times per day, v.o., 2 years treatment.
Other Names:
|
|
ACTIVE_COMPARATOR: 2
Cyclosporin + azathioprine or mofetil mycophenolate +/- steroids (the same treatment that patient had before the study).
|
2 times per day during 2 years
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of subjects that present at least one major clinical event due to graft vascular illness during the first year of the study on both treatment arms.
Time Frame: December 2010
|
December 2010
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Intra-coronary ultrasound, safety and adverse events, Nt-proBNP, left ventricular systolic function, coronary stenosis.
Time Frame: December 2010
|
December 2010
|
Collaborators and Investigators
Investigators
- Principal Investigator: Javier Segovia, cardiologist, Hospital Puerta de Hierro
- Principal Investigator: Nicolás Manito, Cardiologist, Hospital Universitari de Bellvitge
- Principal Investigator: Gregorio Rábago, Cardiologist, Clinica Universitaria de Navarra
- Principal Investigator: Francisco González-Vílchez, Cardiologist, Hospital Marqués de Valdecilla
- Principal Investigator: Juan Delgado, Cardiologist, Hospital 12 de Octubre
- Principal Investigator: Juan Fernández Yañez, Cardiologist, Gregorio Maranon Hospital
- Principal Investigator: Sonia Mirabet, Cardiologist, Hospital Santa Creu i Sant Pau
- Principal Investigator: Eulalia Roig, Cardiologist, Hospital Clinic of Barcelona
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Azathioprine
- Mycophenolic Acid
- Everolimus
Other Study ID Numbers
- EVEROSTAT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.